Recent Updates
Recently added Catalysts
OMER Positive Sentiment

Omeros Corporation Reports Third Quarter 2026 Financial Results

Key Takeaway: Omeros Corporation reported its financial results for the third quarter of 2026. The company highlighted that YARTEMLEA, its approved treatment for TA-TMA, generated gross revenue of $41.8 million. This marks a significant achievement for the company as it continues to address critical medical needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • YARTEMLEA generated $41.8 million in revenue.
  • Omeros reported financial results for Q3 2026.
  • YARTEMLEA is the first approved treatment for TA-TMA.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+411%
120-day peak, hindsight
Typical move
22%
average across 6 past catalysts
Lead asset
OMS906
Phase 2 · Paroxysmal Nocturnal Hemoglobinuria

Full Press Release Details

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2026, which include: Third Quarter and Recent Highlights YARTEMLEA® (narsoplimab-wuug), the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”), an often-lethal complication of stem cell transplantation, generated gross revenue of $41.8 million in the third qua

Frequently Asked Questions

What were Omeros' Q3 2026 financial results?

Omeros reported gross revenue of $41.8 million for Q3 2026.

What is YARTEMLEA?

YARTEMLEA is the first approved treatment for TA-TMA.

When did Omeros report its Q3 2026 results?

Omeros announced its Q3 2026 results on September 30, 2026.

What is TA-TMA?

TA-TMA is a serious complication associated with stem cell transplantation.

Last updated: Nov 16, 2026